An interventional study of Drug-eluting stent implantation and Drug-coated balloon angioplasty in Coronary Artery Disease, sponsored by Chonnam National University Hospital. Recruiting at 8 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.
Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 132nd largest by planned enrollment of the 208 interventional ones that give a count, is one of 10 that started in 2025, is one of 91 with no phase, reaches primary completion later than 51 of the 102 other live ones, and was the 339th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+
Jung-min Ahn · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 20+
Bon-Kwon Koo · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
361 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 15 · Phase 4 95
First in 2003; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 472 across the 208 interventional studies, 1,113 across the 152 observational. Of the 199 that completed or were terminated, 14 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 361 have an industry lead sponsor. The 10 most frequent:
Chonnam National University Hospital is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Chonnam National University Hospital has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Coronary Artery Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02792075Seung-Jung ParkPrognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study | 2026-12 |
| NCT05340361Yonsei UniversityEfficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT | 2026-12-31 |
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT02038660Seung-Jung ParkDrug-Eluting Balloon Registry in Routine Clinical Practice | 2026-12-31 |
| NCT06066450Genoss Co., Ltd.Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).
Drug-eluting stent (DES) is the standard of care for patients with coronary artery disease who are eligible for percutaneous coronary intervention (PCI).1 During long-term follow-up, remained metallic stent strut continuously related with stent-related cardiovascular events.2 As an alternative option to DES, drug-coated balloon (DCB) which has benefit of having shorter DAPT maintenance duration due to the absence of metallic scaffolds and polymers, has been introduced. Based on meta-analysis based on many randomized clinical trials (RCT),3,4 its use has been established in in-stent restenosis of bare-metal stents and DES.5 Furthermore, recent RCTs demonstrated efficacy and safety of DCB in de novo coronary lesions in small vessels with reference vessel size \<3.0mm.6,7 For the patients with de novo, non-complex coronary artery lesions, REC-CAGEFREE I tested the non-inferiority of DCB angioplasty with DES implantation, irrespective of vessel diameter.8 Overall, 2272 patients were randomly assigned to the DCB or the DES group. At 2 years, adverse events occurred in 6.4% of DCB group and 3.4% of DES group and failed to prove the non-inferiority of DCB angioplasty (P for non-inferiority=0.65). Regarding the heterogenous results, it is questionable that DCB angioplasty for large de novo lesions is safe and effective compared with DES implantation.
On this background, the current study aims to compare late-lumen loss (LLL) between DCB and DES to treat de novo coronary artery stenosis by intravascular ultrasound (IVUS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In DES group, latest second-generation DES will be used in accordance with standard practice guideline.
Procedure: Drug-eluting stent implantation
In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.
Procedure: Drug-coated balloon angioplasty
IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups. In DES group, latest second-generation DES will be used in accordance with standard practice guideline.
IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups. In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds.
Late-lumen loss
Mean difference of late-lumen loss between DCB and DES in IVUS
Time frame: 9 months after last patient enrollment
Minimal lumen diameter in QCA
Mean difference of minimal lumen diameter in QCA
Time frame: 9 months after last patient enrollment
% diameter stenosis in QCA
Mean difference of % diameter stenosis in QCA
Time frame: 9 months after last patient enrollment
Minimal lumen diameter in IVUS
Mean difference of minimal lumen diameter in IVUS
Time frame: 9 months after last patient enrollment
Cardiovascular death
Cardiovascular death
Time frame: 1 year after last patient enrollment
All-cause death
All-cause death
Time frame: 1 year after last patient enrollment
Rate of target vessel-MI
Target vessel-MI
Time frame: 1 year after last patient enrollment
Rate of non-fatal MI
Non-fatal MI
Time frame: 1 year after last patient enrollment
Rate of target lesion revascularization
Clinically indicated target lesion revascularization
Time frame: 1 year after last patient enrollment
Rate of target vessel revascularization
Clinically indicated target vessel revascularization
Time frame: 1 year after last patient enrollment
Rate of any revascularization
Any revascularization
Time frame: 1 year after last patient enrollment
Rate of vessel or stent thrombosis
Definite or probable thrombosis
Time frame: 1 year after last patient enrollment
Cardiovascular death or target vessel-related myocardial infarction
A composite of cardiovascular death or target vessel-related myocardial infarction
Time frame: 1 year after last patient enrollment
All-cause death or non-fatal MI
A composite of all-cause death or non-fatal myocardial infarction
Time frame: 1 year after last patient enrollment
Target vessel failure
A composite of cardiovascular death, target-vessel myocardial infarction, and clinically indicated target vessel revascularization
Time frame: 1 year after last patient enrollment
Target lesion failure
A composite of cardiovascular death, target-vessel myocardial infarction, and clinically indicated target lesion revascularization
Time frame: 1 year after last patient enrollment
Cardiovascular death, target-vessel MI, or vessel or stent thrombosis
A composite of cardiovascular death, target-vessel MI, or vessel or stent thrombosis
Time frame: 1 year after last patient enrollment
All-cause death, non-fatal myocardial infarction, or target vessel revascularization
A composite of all-cause death, non-fatal myocardial infarction, or target vessel revascularization
Time frame: 1 year after last patient enrollment
BARC type 2, 3, or 5 bleeding
BARC type 2, 3, or 5 bleeding
Time frame: 1 year after last patient enrollment
Cerebrovascular accident
Ischemic stroke, hemorrhagic stroke, or transient ischemic attack
Time frame: 1 year after last patient enrollment
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Yes After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After publication of main paper.
Access criteria: Executive Committee will discuss to share the de-identified data upon reasonable requests.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 28 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chonnam National University Hospital